WO2004009622A3 - Protein complexes of cellular networks underlying the development of cancer and other diseases - Google Patents

Protein complexes of cellular networks underlying the development of cancer and other diseases Download PDF

Info

Publication number
WO2004009622A3
WO2004009622A3 PCT/EP2003/007835 EP0307835W WO2004009622A3 WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3 EP 0307835 W EP0307835 W EP 0307835W WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
cancer
development
diseases
protein complexes
Prior art date
Application number
PCT/EP2003/007835
Other languages
French (fr)
Other versions
WO2004009622A2 (en
Inventor
Alejandro Merino
Tewis Bouwmeester
Andreas Bauer
Gerard Drewes
Martina Marzioch
Ulrich Kruse
Giulio Superti-Furga
Dirk Eberhard
Heinz Ruffner
Scott Hobson
Gerd Helftenbein
Cristina Cruciat
Original Assignee
Cellzome Ag
Alejandro Merino
Tewis Bouwmeester
Andreas Bauer
Gerard Drewes
Martina Marzioch
Ulrich Kruse
Giulio Superti-Furga
Dirk Eberhard
Heinz Ruffner
Scott Hobson
Gerd Helftenbein
Cristina Cruciat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02016123.8 priority Critical
Priority to EP02016111.3 priority
Priority to EP02016109 priority
Priority to EP02016128 priority
Priority to EP02016109.7 priority
Priority to EP02016111 priority
Priority to EP02016123 priority
Priority to EP02016128.7 priority
Priority to EP02016427 priority
Priority to EP02016427.3 priority
Application filed by Cellzome Ag, Alejandro Merino, Tewis Bouwmeester, Andreas Bauer, Gerard Drewes, Martina Marzioch, Ulrich Kruse, Giulio Superti-Furga, Dirk Eberhard, Heinz Ruffner, Scott Hobson, Gerd Helftenbein, Cristina Cruciat filed Critical Cellzome Ag
Publication of WO2004009622A2 publication Critical patent/WO2004009622A2/en
Publication of WO2004009622A3 publication Critical patent/WO2004009622A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

The present invention relates to protein complexes involved in cellular processes which have been shown to be critical for the development of various forms of cancer, component proteins of the said complexes, fragments and derivatives of the component proteins, and antibodies specific to the complexes. The present invention also relates to methods for use of the complexes and their interacting proteins in, inter alia, screening, diagnosis, and therapy, as well as to methods of preparing the complexes.
PCT/EP2003/007835 2002-07-19 2003-07-18 Protein complexes of cellular networks underlying the development of cancer and other diseases WO2004009622A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP02016111.3 2002-07-19
EP02016109 2002-07-19
EP02016128 2002-07-19
EP02016109.7 2002-07-19
EP02016111 2002-07-19
EP02016123.8 2002-07-19
EP02016123 2002-07-19
EP02016128.7 2002-07-19
EP02016427.3 2002-07-22
EP02016427 2002-07-22

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003281515A AU2003281515A1 (en) 2002-07-19 2003-07-18 Protein complexes of cellular networks underlying the development of cancer and other diseases

Publications (2)

Publication Number Publication Date
WO2004009622A2 WO2004009622A2 (en) 2004-01-29
WO2004009622A3 true WO2004009622A3 (en) 2004-09-10

Family

ID=30773697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007835 WO2004009622A2 (en) 2002-07-19 2003-07-18 Protein complexes of cellular networks underlying the development of cancer and other diseases

Country Status (2)

Country Link
AU (1) AU2003281515A1 (en)
WO (1) WO2004009622A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2004094647A2 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
WO2005124360A2 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein tebp as a marker for breast cancer
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
SI1791565T1 (en) 2004-09-23 2016-08-31 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2007035494A2 (en) * 2005-09-16 2007-03-29 The Regents Of The University Of California Inducing expression of puma to reduce joint inflammation in the treatment of arthritis
EP1986675A2 (en) * 2006-02-24 2008-11-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
WO2008104805A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2012038744A2 (en) * 2010-09-22 2012-03-29 Genome Research Limited Detecting mutations
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc antibody and conjugated drug, compound, method of treatment and pharmaceutical composition
MX2016007825A (en) 2013-12-16 2016-09-07 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, the method of preparation of a conjugate of formula, formula A1 conjugate, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition and use of a conjugate or a composition
AU2015358532A1 (en) 2014-12-03 2017-06-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3458101A1 (en) 2016-05-20 2019-03-27 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221A1 (en) 2016-05-27 2019-04-10 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002092626A2 (en) * 2001-05-15 2002-11-21 Cellzome Ag Cleavage and polyadenylation complex of precursor mrna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002092626A2 (en) * 2001-05-15 2002-11-21 Cellzome Ag Cleavage and polyadenylation complex of precursor mrna

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUMANN PETER ET AL: "Pot1, the putative telomere end-binding protein in fission yeast and humans", SCIENCE (WASHINGTON D C), vol. 292, no. 5519, 11 May 2001 (2001-05-11), pages 1171 - 1175, XP002261020, ISSN: 0036-8075 *
BLACKBURN ELIZABETH H: "Switching and signaling at the telomere", CELL, vol. 106, no. 6, 21 September 2001 (2001-09-21), pages 661 - 673, XP002261021, ISSN: 0092-8674 *
GAVIN A-C ET AL: "Functional organization of the yeast proteome by systematic analysis of protein complexes", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, January 2002 (2002-01-01), pages 141 - 147, XP002958851, ISSN: 0028-0836 *
HO Y ET AL: "Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, 10 January 2002 (2002-01-10), pages 180 - 183, XP002250082, ISSN: 0028-0836 *
KUMAR ANUJ ET AL: "Protein complexes take the bait.", NATURE. ENGLAND 10 JAN 2002, vol. 415, no. 6868, 10 January 2002 (2002-01-10), pages 123 - 124, XP002261019, ISSN: 0028-0836 *
PAWSON^A^ ^B T ET AL: "Interaction domains: from simple binding events to complex cellular behavior", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 513, no. 1, 20 February 2002 (2002-02-20), pages 2 - 10, XP004344928, ISSN: 0014-5793 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
AU2003281515A1 (en) 2004-02-09
WO2004009622A2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
RU2005127361A (en) The system and method for evaluating formation parameters
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
HRP20080053A2 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
NO20063580L (en) Sandaggregeringsreagenser modified sand as well as methods of preparation and use thereof
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
BR0309254A (en) Use of an anti-CTLA-4 antibody
RU2007126832A (en) Pyrid-2-ones useful as inhibitors of protein kinases family tes for treating inflammatory, proliferative and immunologically mediated diseases
IL142691A (en) Use of an antibody which binds to ailim protein in the manufacture of medicament for preventing, treating or prophylaxis of graft versus host reaction
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
PL393641A1 (en) Host cells, method for producing a polypeptide, antibody, pharmaceutical composition and method for treating cancer
CY1118693T1 (en) Anti-aktivinis a AND USES these
HRP20130922T1 (en) Fully human antibodies against human 4-1bb (cd137)
CA2202028A1 (en) Tie-2 ligands, methods of making and uses thereof
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
EP1999149A4 (en) Anti-igf-ir antibodies and uses thereof
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
RU2007109108A (en) Combinations for the treatment of diseases involving cell proliferation
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
RU2004135061A (en) Additive for cement having improved plasticizing properties, and method for its preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP